Fuda Cancer Hospital
Melanoma treatment cost in China is influenced by the disease stage and clinical approach, with essential treatments like wide excision of melanoma ranging from $4,500 to $9,500. Natural killer cell therapy costs between Price on request and Price on request for advanced cases. Patients can save approximately 60-80% compared to US prices. Leading medical hubs include Guangzhou, Beijing, and Xiamen.
Typical Melanoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced melanoma find high value in Guangzhou's multidisciplinary centers. Fuda Cancer Hospital is best for late-stage cases, offering NanoKnife and cryosurgery for complex tumors. For localized lesions, Jinshazhou Hospital provides expert ablation techniques under Director Liuying. High-tier Class 3A hospitals ensure JCI-accredited safety standards at most competitive rates. Specialized cellular therapies remain significantly more affordable here than in Western clinics.
| China | Turkey | Austria | |
| Mohs microsurgery | from $2,400 | from $2,200 | from $4,000 |
| Melanoma surgery | from $6,200 | from $3,500 | from $9,500 |
| Actinium-225 Therapy | from $13,800 | from $22,955 | from $55,000 |
| Immunotherapy with Keytruda (Pembolizumab) | from $6,200 | from $3,300 | from $15,000 |
| Wide excision of melanoma | from $4,500 | from $4,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Melanoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Melanoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Melanoma treatment journey.
Dr. Liuying directs the Oncology Ward at Jinshazhou Hospital in Guangzhou. She specializes in minimally invasive ablation for liver, lung, and colorectal cancers. Her primary focus includes hepatocellular carcinoma and melanoma liver metastasis. Dr. Liuying contributed to the national expert consensus on thermal ablation for lung tumors.
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Dr. Niu Lizhi is the President and chief surgeon at Fuda Cancer Hospital in Guangzhou. He has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures. Dr. Niu specializes in minimally invasive oncology for lung, pancreatic, and liver cancers. He treats patients ranging from early childhood through age 94.
Written by Veronika Kazina
China treats melanoma using surgery, immunotherapy, and targeted therapies. Specialized centers focus on aggressive acral and mucosal subtypes. JCI-accredited facilities like Fuda Cancer Hospital offer over 10 minimally invasive options. These include cryosurgery and NanoKnife technology for advanced cases.
Bookimed Expert Insight: Analysis of clinical availability suggests Guangzhou is a hub for specialized melanoma interventional oncology. Dr. Liuying at Jinshazhou Hospital specifically integrates microwave ablation with traditional oncology. This focus on thermal ablation offers an alternative for patients who cannot undergo standard surgical resection.
Patient Consensus: Patients note that seeking treatment at major tertiary hospitals ensures access to critical staging tools like sentinel lymph node biopsies. Many emphasize confirming genetic mutation status through reliable labs before starting targeted drug regimens.
Modern immunotherapy using PD-1 and PD-L1 inhibitors is widely available and clinically effective in China. Patients can access over 20 approved medications. These include global brands like Keytruda and domestic alternatives like Toripalimab. Studies show success rates comparable to international protocols.
Bookimed Expert Insight: China has specialized protocols for acral and mucosal melanoma, which are more common in Asian populations. JCI-accredited facilities often combine PD-1 inhibitors weight-based dosing with minimally invasive therapies like cryosurgery. This multidisciplinary approach can improve local tumor control where standard surgery alone might be insufficient.
Patient Consensus: Patients find that accessing domestic PD-1 inhibitors in major cities like Guangzhou is straightforward and significantly more affordable. Many emphasize the importance of upfront biomarker testing to ensure the chosen drug matches their specific cancer profile.
Melanoma in China primarily affects the palms, soles, and mucous membranes. This contrasts with Western populations where sun-exposure patterns dominate. Chinese patients often present at advanced stages. Genetic mutations like KIT and NRAS are more frequent than the BRAF mutations seen in Caucasians.
Bookimed Expert Insight: Data from Fuda Cancer Hospital highlights a push for specialized minimally invasive therapies. They offer NanoKnife and microwave hyperthermia for late-stage cases. Dr. Liuying at Jinshazhou Hospital manages complex melanoma liver metastases using interventional ablation. This specialized focus on advanced-stage intervention mirrors the clinical reality of China’s later diagnosis patterns.
Patient Consensus: Patients note that acral melanoma on the hands or feet often goes ignored for years before confirmation. Experts recommend seeking evaluation at tertiary centers in major cities like Guangzhou to access advanced interventional oncology.
International patients can join melanoma clinical trials in China if they meet specific medical criteria. Chinese centers specialize in cellular therapies like Tumor-Infiltrating Lymphocyte (TIL) treatment. Global eligibility encompasses patients from over 100 countries. Participation requires detailed biopsy reports and scans showing measurable lesions.
Bookimed Expert Insight: Focus on Guangzhou academic centers where specialists like Dr. Liuying manage melanoma liver metastasis. These hospitals treat 30,000+ international patients annually and often combine standard immunotherapy with local interventions. Seeking trials directly through directors of oncology wards often bypasses the lack of centralized English-language recruitment databases.
Patient Consensus: Patients note it is essential to ask about English protocols since documents are often only in Chinese. Clarifying long-term visa options early is vital because clinical trials require extended hospital stays.
Specialized melanoma care in China centers on JCI-accredited facilities in Guangzhou and Beijing. Hospitals like Fuda Cancer Hospital and Jinshazhou Hospital offer advanced minimally invasive treatments. These include NanoKnife and cryosurgery. Chinese oncology hubs integrate surgical resection with multidisciplinary immunotherapy and cell-based therapies.
Bookimed Expert Insight: Focus on Guangzhou clinics if you require non-surgical alternatives to chemotherapy. Fuda Cancer Hospital uses over 10 types of minimally invasive therapies. This is ideal for late-stage cases where traditional surgery is not possible. Dr. Liuying at Jinshazhou Hospital integrates microwave ablation specifically for metastatic melanoma spread. These specialized protocols are often more accessible in Guangzhou than in packed Beijing centers.
Patient Consensus: Patients emphasize the need for a bilingual concierge or translator when visiting public oncology centers. Many note that surgeon experience with specific mutations like BRAF+ is more important than hospital prestige.
Treatment protocols for acral and mucosal melanoma differ significantly from cutaneous disease in surgical margins and systemic response. While cutaneous types often respond to immunotherapy, acral and mucosal variants frequently require KIT-targeted therapies and specialized surgeries to preserve function in palms, soles, or mucosal membranes.
Bookimed Expert Insight: While Western protocols focus heavily on PD-1 inhibitors, Chinese JCI-accredited centers like Fuda Cancer Hospital utilize a multi-modal approach. Data shows they prioritize combining minimally invasive techniques like NanoKnife or cryosurgery with systemic treatments. This is particularly effective for mucosal melanomas in difficult-to-reach areas where traditional wide-margin surgery is physically impossible.
Patient Consensus: Patients with acral melanoma emphasize that finding a surgeon who prioritizes limb function is just as vital as clearing the cancer. Those treated for rare subtypes note that specialized molecular testing was the turning point in their treatment plan.
Advanced melanoma treatment in China utilizes immunotherapy, targeted drugs for specific genetic mutations, and advanced ablation techniques. Beyond surgery, patients access checkpoint inhibitors like Toripalimab and Pembrolizumab. Specialized centers integrate cryosurgery and NanoKnife technology. These options aim to manage metastatic cases and mucosal subtypes effectively.
Bookimed Expert Insight: China is a unique hub for combining traditional immunotherapy with advanced ablation. Fuda Cancer Hospital has treated over 30,000 patients using `3C` therapy (Cryosurgery, Cancer Microvascular Intervention, and Combined Immunotherapy). This approach often yields results for late-stage patients who have exhausted standard chemotherapy options elsewhere.
Patient Consensus: Patients emphasize getting genetic testing early to check for BRAF status. Some note that domestic immunotherapy options like Toripalimab can lead to long-term remission for Stage 4 cases.
China specialises in treating acral and mucosal melanoma. In contrast, Australian care focuses on UV-related cutaneous types. Chinese protocols frequently use minimally invasive ablations and domestic immunotherapy for advanced stages. JCI-accredited clinics in Guangzhou serve over 30,000 international patients using interventional oncology techniques.
Bookimed Expert Insight: Chinese oncology centres often integrate more than 10 types of minimally invasive therapies. Dr Liuying and other specialists use thermal ablation as a primary alternative to chemotherapy. This approach differs from Australia, where surgical excision and systemic immunotherapy remain the standard frontline choices.
Patient Consensus: Patients emphasised the need for expert pathology reviews to confirm Breslow thickness and margins. In China, verifying that a hospital has a dedicated skin cancer team is essential.
Melanoma treatment in China focuses on surgical excision and minimally invasive therapies. National centres combine immunotherapy with specialised ablative techniques to manage primary tumours and metastatic disease. Modern protocols frequently use targeted drugs and precision radiotherapy for cases that have spread.
Bookimed Expert Insight: Chinese oncology centres like Fuda Cancer Hospital specialise in treating late-stage melanoma. They avoid traditional chemotherapy. Instead, they manage over 30,000 patients annually using more than 10 types of minimally invasive therapies. This volume allows surgeons to develop deep expertise in techniques like irreversible electroporation.
Patient Consensus: Patients value the alternative treatments like cryoablation and interventional oncology available in Guangzhou. Many note the high level of medical research participation by specialists like Dr Liuying.
Leading Chinese hospitals for melanoma include JCI-accredited Fuda Cancer Hospital and Xiamen Humanity Hospital. These centres focus on immunotherapy and minimally invasive techniques like NanoKnife. Specialists there treat stage 4 cases using cryosurgery and multidisciplinary care models.
Bookimed Expert Insight: China's oncology landscape is unique for its high-volume adoption of ablative technologies. While Australian patients often seek surgery or drugs, Fuda Cancer Hospital is popular. It has served over 30,000 international patients using NanoKnife and cryosurgery. These methods treat tumours that are difficult to remove surgically. This volume helps surgeons maintain high proficiency in these specialised local treatments.
Patient Consensus: Patients recommend selecting university-affiliated hospitals. These should provide medical oncology, surgery, and pathology in one location. Australians should confirm English-language support and clear follow-up plans before travelling to China.
The China National Drug Administration (CNDA) approved the immunotherapy drugs Keytruda and Opdivo in 2018. Leading oncology centres like Fuda Cancer Hospital in Guangzhou provide these treatments for melanoma. These therapies are approved for use in advanced cases.
Bookimed Expert Insight: Patients in China often have access to many local and international immunotherapies. While Keytruda and Opdivo are standard, JCI-accredited facilities like Fuda Cancer Hospital serve over 30,000 international patients. These clinics often combine immunotherapy with minimally invasive therapies like NanoKnife or cryosurgery for complex metastases.
Patient Consensus: Patients recommend confirming if specific drugs like Keytruda are currently in a hospital's formulary. They suggest checking the import status and total out-of-pocket costs before travelling for treatment.
Melanoma patients in China can access several targeted therapies for BRAF and NRAS mutations. Clinicians prescribe BRAF inhibitors like Vemurafenib. They also use combination treatments like Dabrafenib with Trametinib. Tunlametinib is also available. It is the first targeted drug approved in China for NRAS-mutant cases.
Bookimed Expert Insight: Chinese oncology centres like Fuda Cancer Hospital focus on combining targeted drugs with minimally invasive local therapies. Specialists often use microwave ablation or NanoKnife alongside systemic drugs to treat melanoma metastases. This dual approach helps manage regional tumours when traditional chemotherapy is not the preferred path.
Patient Consensus: Patients emphasise the need for molecular testing for BRAF mutations before selecting a clinic. Many note that combination therapies are preferred over single-agent drugs for treating advanced melanoma in China.